Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Centaurus Biopharma Co., Ltd.

Lianyungang Runzhong Pharmaceutical Co., Ltd.

Lainyungang Runzhong Pharmaceutical Co., Ltd.

Xinlu Li

Xiquan Zhang

Rui Zhao

Yongxin Han

Dengming Xiao

Xijie Liu

Xinhe Xu

Feng Gong

Fei Liu

Shanchun Wang

Hongmei Gu

Yanlong Liu

Zhilin Chen

Xifeng Lu

Wenjun Geng

Huihui Zhang

Shang Wang

Yi Xu

Shanliang Zhu

Lihui Dong

Haishan Zang

Jianghui Jing

Peng Sun

Xiandong Zhao

Min Li

The present application relates to the field of medicine, and relates to crystals of quinoline derivatives, and in particular, to crystals of a quinoline derivative anhydride and a solvate, as well as a method for preparing the crystals, pharmaceutical compositions containing the crystals, and a use thereof in the field of medicine. The present application further provides a preparation method therefor, which has a high yield, has mild crystallization conditions, is suitable for industrial production, and may better meet the needs of the pharmaceutical industry.

Crystals of quinolone derivatives

A solid pharmaceutical composition comprising a TLR7 agonist 2-butoxy-7-(4-(pyrrolidin-1-ylmethyl)benzyl)-5H-pyrrolo[3,2-d]pyrimidin-4-amine, a preparation method therefor, and an medical application thereof. The solid pharmaceutical composition has excellent stability and dissolution properties.

Solid pharmaceutical composition comprising TLR7 agonist

The present invention discloses a crystal of citrate salt of pyridine-substituted 2-aminopyridine-based protein kinase inhibitors, in particular, to crystal of 5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-4'-methoxy-6&#x2032;-((S)-2-methylpiperazin-1-yl)-3,3&#x2032;-bipyridin-6-amine citrate salt, a method for preparation thereof, a crystalline composition and a pharmaceutical composition comprising the crystal, and further discloses the use of crystals of citrate salt of the compound of Formula I in protein kinase-related diseases. The crystals of citrate salt according to the present invention are superior to 5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-4&#x2032;-methoxy-6&#x2032;-((S)-2-methylpiperazin-1-yl)-3,3&#x2032;-bipyridin-6-amine or other salts of 5-((R)-1-(2,6-dichloro-3-fluorophenyl)ethoxy)-4&#x2032;-methoxy-6&#x2032;-((S)-2-methylpiperazin-1-yl)-3,3&#x2032;-bipyridin-6-amine in at least one aspect of bioavailability, hygroscopicity, stability, solubility, purity, ease of preparation, and the like.

Pyridine substituted 2-aminopyridine protein kinase inhibitor crystal

The present invention discloses pharmaceutically acceptable acid salts of pyridine-substituted 2-aminopyridine derivatives as protein kinase inhibitors, preparation methods, pharmaceutical compositions thereof, and use thereof for the treatment of diseases associated with protein kinase.

Pyridine-substituted 2-aminopyridine protein kinase inhibitors

Growing community of inventors

Lianyungang, China

Xinlu Li